Your browser is no longer supported. Please, upgrade your browser.
Settings
QURE uniQure N.V. daily Stock Chart
QURE [NASD]
uniQure N.V.
Index- P/E- EPS (ttm)-3.75 Insider Own1.00% Shs Outstand44.47M Perf Week6.61%
Market Cap2.05B Forward P/E- EPS next Y-1.59 Insider Trans-14.29% Shs Float39.77M Perf Month11.75%
Income-165.80M PEG- EPS next Q2.02 Inst Own94.90% Short Float7.22% Perf Quarter20.68%
Sales6.10M P/S336.68 EPS this Y-32.80% Inst Trans0.83% Short Ratio7.12 Perf Half Y-28.01%
Book/sh5.12 P/B9.01 EPS next Y-137.30% ROA-41.50% Target Price70.21 Perf Year-9.38%
Cash/sh6.28 P/C7.35 EPS next 5Y- ROE-59.60% 52W Range34.38 - 76.69 Perf YTD-35.65%
Dividend- P/FCF- EPS past 5Y-1.30% ROI-33.70% 52W High-40.04% Beta1.26
Dividend %- Quick Ratio8.60 Sales past 5Y3.50% Gross Margin- 52W Low33.74% ATR2.46
Employees248 Current Ratio8.60 Sales Q/Q80.00% Oper. Margin- RSI (14)63.79 Volatility6.64% 5.92%
OptionableYes Debt/Eq0.16 EPS Q/Q-108.70% Profit Margin- Rel Volume0.93 Prev Close46.11
ShortableYes LT Debt/Eq0.16 Earnings- Payout- Avg Volume403.19K Price45.98
Recom1.80 SMA208.40% SMA5015.32% SMA200-5.09% Volume277,695 Change-0.28%
Nov-11-20Initiated Berenberg Buy
Nov-09-20Initiated Jefferies Buy $55
Nov-04-20Initiated Cantor Fitzgerald Overweight $65
Oct-23-20Initiated RBC Capital Mkts Outperform $61
Aug-25-20Initiated Raymond James Strong Buy $75
Jul-31-20Upgrade Robert W. Baird Neutral → Outperform $57
Jun-25-20Downgrade Wells Fargo Overweight → Equal Weight $56
Jun-25-20Downgrade Robert W. Baird Outperform → Neutral $58
Jun-25-20Downgrade Mizuho Buy → Neutral $90 → $61
Dec-03-19Initiated Goldman Buy
Dec-03-19Initiated Cowen Outperform
Nov-05-19Initiated Credit Suisse Outperform
Oct-11-19Initiated Stifel Buy
Sep-25-19Initiated Bernstein Outperform $73
Sep-12-19Initiated Mizuho Buy
Jul-30-19Downgrade Guggenheim Buy → Neutral
Jul-08-19Reiterated Cantor Fitzgerald Overweight $81 → $94
Apr-12-19Initiated Piper Jaffray Overweight $80
Mar-29-19Initiated Robert W. Baird Outperform $85
Mar-04-19Reiterated Chardan Capital Markets Buy $70 → $100
Nov-19-20 04:37PM  
09:10AM  
Nov-12-20 11:01AM  
Nov-04-20 10:46AM  
07:05AM  
Oct-29-20 10:55AM  
Oct-27-20 10:25AM  
07:05AM  
Oct-26-20 11:54PM  
03:44PM  
Oct-19-20 12:31PM  
Oct-13-20 07:05AM  
Sep-30-20 07:05AM  
Sep-25-20 07:05AM  
Sep-23-20 10:28AM  
Sep-15-20 09:06AM  
Sep-03-20 07:05AM  
Aug-31-20 10:21PM  
08:56AM  
Aug-26-20 10:44PM  
07:05AM  
Jul-30-20 10:25AM  
07:05AM  
Jul-27-20 12:31PM  
Jul-08-20 12:38PM  
Jun-25-20 08:26AM  
07:54AM  
Jun-24-20 06:28PM  
04:05PM  
Jun-19-20 07:05AM  
Jun-17-20 04:05PM  
Jun-15-20 07:05AM  
Jun-01-20 09:29AM  
May-29-20 07:38PM  
May-18-20 07:49AM  
May-14-20 07:00AM  
May-11-20 11:13PM  
Apr-29-20 08:45AM  
07:00AM  
Apr-28-20 04:51PM  
Apr-27-20 12:32PM  
Apr-24-20 04:21PM  
Apr-21-20 10:47AM  
Apr-17-20 07:00AM  
Mar-30-20 07:00AM  
Mar-28-20 09:10PM  
Mar-26-20 12:36PM  
07:00AM  
Mar-18-20 06:01AM  
Mar-03-20 07:00AM  
Mar-02-20 05:45PM  
04:05PM  
04:05PM  
Feb-27-20 07:00AM  
Feb-26-20 08:41AM  
Feb-21-20 10:48AM  
Feb-20-20 12:31PM  
Feb-04-20 07:00AM  
Jan-31-20 07:00AM  
Jan-10-20 02:20PM  
Jan-07-20 12:12PM  
Dec-24-19 09:30AM  
Dec-19-19 10:27AM  
07:00AM  
Dec-17-19 09:11AM  
07:02AM  
06:00AM  
Dec-16-19 09:34AM  
Dec-08-19 04:00PM  
Dec-06-19 09:33AM  
Dec-05-19 04:32PM  
10:12AM  
03:49AM  
Dec-04-19 09:42AM  
Dec-03-19 11:53AM  
Dec-02-19 07:00AM  
Nov-30-19 07:02PM  
Nov-22-19 10:16AM  
Nov-07-19 09:45AM  
Nov-06-19 09:16AM  
Nov-05-19 07:00AM  
Nov-01-19 07:00AM  
Oct-31-19 07:00AM  
Oct-30-19 11:46AM  
10:38AM  
Oct-29-19 12:37PM  
Oct-28-19 08:15AM  
07:00AM  
Oct-25-19 09:15AM  
Oct-02-19 09:33AM  
Oct-01-19 01:43PM  
Sep-30-19 11:10AM  
Sep-27-19 07:00AM  
Sep-26-19 10:34AM  
Sep-05-19 08:39PM  
08:12AM  
Sep-04-19 04:02PM  
Sep-03-19 07:00AM  
Aug-30-19 08:32AM  
07:00AM  
uniQure N.V., a gene therapy company, engages in the development and commercialization of treatments for patients suffering from genetic and other diseases in the Netherlands. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180, an one-time intravenously-administered gene therapy candidate, which is in preclinical stage for the treatment of hemophilia A; and AMT-190, an IV-administered adeno-associated virus 5-based gene therapy for the treatment of Fabry disease. In addition, it engages in developing AMT-150, a gene therapy candidate for the treatment of Spinocerebellar Ataxia Type 3 disease. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kapusta Matthew CCEO, CFO, Managing DirectorNov 18Option Exercise7.533,21624,216283,780Nov 20 04:58 PM
Kapusta Matthew CCEO, CFO, Managing DirectorNov 18Sale43.6910,313450,579273,467Nov 20 04:58 PM
Kapusta Matthew CCEO, CFO, Managing DirectorOct 14Sale35.865,250188,256280,564Oct 16 04:10 PM
Gut RobertChief Medical OfficerSep 21Sale39.124,352170,25041,523Sep 22 09:48 AM
Kuta Alexander Edward IIIExecutive VP, OperationsSep 18Sale41.182,23091,83156,860Sep 22 09:54 AM
Kapusta Matthew CCEO, CFO, Managing DirectorSep 16Sale40.667,500304,939285,814Sep 18 01:41 PM
Kapusta Matthew CCEO, CFO, Managing DirectorAug 25Sale40.2730012,081293,314Aug 27 05:00 PM
Kapusta Matthew CCEO, CFO, Managing DirectorAug 19Sale39.114,300168,175293,614Aug 21 04:32 PM
Kapusta Matthew CCEO, CFO, Managing DirectorJul 22Sale42.315,626238,025297,914Jul 24 04:41 PM
Gut RobertChief Medical OfficerJun 23Option Exercise39.1226,8751,051,34472,750Jun 24 04:21 PM
Gut RobertChief Medical OfficerJun 23Sale70.0026,8751,881,25045,875Jun 24 04:21 PM
Kapusta Matthew CCEO, CFO, Managing DirectorJun 17Sale66.047,501495,366303,540Jun 22 04:43 PM
Kapusta Matthew CCEO, CFO, Managing DirectorMay 20Sale59.947,501449,580311,041May 22 05:13 PM
KLEMT CHRISTIANChief Accounting OfficerApr 24Option Exercise26.412,25059,42359,268Apr 28 04:29 PM
KLEMT CHRISTIANChief Accounting OfficerApr 24Sale60.002,250135,00057,018Apr 28 04:29 PM
Kapusta Matthew CCEO, CFO, Managing DirectorApr 22Option Exercise7.539,37670,601327,918Apr 24 04:46 PM
Kapusta Matthew CCEO, CFO, Managing DirectorApr 22Sale56.879,376533,205318,542Apr 24 04:46 PM
Kapusta Matthew CCEO, CFO, Managing DirectorMar 18Option Exercise7.535,62642,364324,168Mar 20 01:16 PM
Kapusta Matthew CCEO, CFO, Managing DirectorMar 18Sale41.485,626233,352318,542Mar 20 01:16 PM
KLEMT CHRISTIANChief Accounting OfficerMar 04Option Exercise26.4115,750415,95872,768Mar 06 10:07 AM
KLEMT CHRISTIANChief Accounting OfficerMar 04Sale52.2915,750823,50057,018Mar 06 10:07 AM
Kapusta Matthew CCEO, CFO, Managing DirectorFeb 19Sale64.567,501484,256284,753Feb 21 10:03 AM
Soteropoulos PaulaDirectorFeb 05Sale60.952,122129,3322,423Feb 05 01:19 PM
Kapusta Matthew CCEO, CFO, Managing DirectorJan 31Sale57.983,872224,499264,541Jan 31 03:45 PM
Astley-Sparke PhilipDirectorJan 30Sale59.2380747,7996,005Jan 30 09:39 PM
Kapusta Matthew CCEO, CFO, Managing DirectorJan 30Sale59.3123,5831,398,646268,413Jan 31 03:45 PM
Kapusta Matthew CCEO, CFO, Managing DirectorJan 29Sale61.9423,5831,460,794291,996Jan 31 03:45 PM
Kuta Alexander Edward IIIExecutive VP, OperationsJan 28Sale62.141,47891,84840,100Jan 30 09:36 PM
Kapusta Matthew CCEO, CFO, Managing DirectorJan 28Sale61.9223,5831,460,221315,579Jan 29 11:24 AM
Kaye JackDirectorJan 28Sale62.2080650,13314,128Jan 30 09:32 PM
Balachandran MadhavanDirectorJan 28Sale62.2080750,1956,005Jan 30 09:23 PM
Soteropoulos PaulaDirectorJan 28Sale62.1980750,1874,545Jan 30 09:15 PM
van Deventer SanderEVP, Research & Product Dev.Jan 28Sale61.612,227137,21443,127Jan 30 09:11 PM
SCHAFFER DAVIDDirectorJan 28Sale62.2780650,19044,915Jan 30 09:06 PM
KLEMT CHRISTIANChief Accounting OfficerJan 28Sale61.4711,975736,07242,564Jan 30 09:02 PM
Springhorn Jeremy P.DirectorJan 28Sale62.1980750,1906,005Jan 30 08:57 PM
Meek David D.DirectorJan 28Sale62.1972244,9032,508Jan 30 08:54 PM
Gut RobertChief Medical OfficerJan 28Sale62.1959637,06527,885Jan 29 06:02 PM
Gut RobertChief Medical OfficerJan 27Sale60.016,897413,88928,481Jan 29 06:02 PM
Kapusta Matthew CCEO, CFO, Managing DirectorJan 27Sale65.5528,2891,854,280339,162Jan 29 11:24 AM
Kuta Alexander Edward IIIExecutive VP, OperationsJan 15Option Exercise5.314,00021,24045,578Jan 17 09:39 AM
Kuta Alexander Edward IIIExecutive VP, OperationsJan 15Sale68.974,000275,88041,578Jan 17 09:39 AM
Soteropoulos PaulaDirectorJan 07Sale72.183,000216,5405,352Jan 08 01:48 PM
Kapusta Matthew CCEO, CFO, Managing DirectorDec 18Option Exercise7.537,33955,263374,991Dec 20 04:13 PM
Kapusta Matthew CCEO, CFO, Managing DirectorDec 18Sale70.097,540528,510367,451Dec 20 04:13 PM
Kuta Alexander Edward IIIExecutive VP, OperationsDec 16Option Exercise5.314,00021,24045,578Dec 17 04:09 PM
Kuta Alexander Edward IIIExecutive VP, OperationsDec 16Sale74.594,000298,35641,578Dec 17 04:09 PM
Soteropoulos PaulaDirectorDec 13Option Exercise5.372,00010,74010,352Dec 17 04:06 PM
Soteropoulos PaulaDirectorDec 13Sale70.502,000141,0008,352Dec 17 04:06 PM
Soteropoulos PaulaDirectorDec 09Sale67.502,500168,7508,352Dec 09 06:30 PM
Soteropoulos PaulaDirectorDec 06Sale64.269,082583,60010,852Dec 09 06:30 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.